145 related articles for article (PubMed ID: 11431184)
1. Cholesteryl ester transfer protein as a protective factor against vascular disease in hemodialysis patients.
Kimura H; Miyazaki R; Suzuki S; Gejyo F; Yoshida H
Am J Kidney Dis; 2001 Jul; 38(1):70-6. PubMed ID: 11431184
[TBL] [Abstract][Full Text] [Related]
2. [Risk factors for atherosclerotic vascular disease in patients on maintenance hemodialysis--with especial respect to reverse cholesterol transport system and hyperhomocysteinemia].
Kimura H; Yoshida H
Rinsho Byori; 2002 Aug; 50(8):793-801. PubMed ID: 12373816
[TBL] [Abstract][Full Text] [Related]
3. Hepatic lipase mutation may reduce vascular disease prevalence in hemodialysis patients with high CETP levels.
Kimura H; Miyazaki R; Imura T; Masunaga S; Suzuki S; Gejyo F; Yoshida H
Kidney Int; 2003 Nov; 64(5):1829-37. PubMed ID: 14531818
[TBL] [Abstract][Full Text] [Related]
4. A low prevalence of coronary heart disease among subjects with increased high-density lipoprotein cholesterol levels, including those with plasma cholesteryl ester transfer protein deficiency.
Moriyama Y; Okamura T; Inazu A; Doi M; Iso H; Mouri Y; Ishikawa Y; Suzuki H; Iida M; Koizumi J; Mabuchi H; Komachi Y
Prev Med; 1998; 27(5 Pt 1):659-67. PubMed ID: 9808796
[TBL] [Abstract][Full Text] [Related]
5. Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation.
Inazu A; Brown ML; Hesler CB; Agellon LB; Koizumi J; Takata K; Maruhama Y; Mabuchi H; Tall AR
N Engl J Med; 1990 Nov; 323(18):1234-8. PubMed ID: 2215607
[TBL] [Abstract][Full Text] [Related]
6. [Genetic variation of the cholesterol ester transfer protein gene and the prevalence of coronary artery disease. The AtheroGene case control study].
Blankenberg S; Tiret L; Bickel C; Schlitt A; Jungmair W; Genth-Zotz S; Lubos E; Espinola-Klein C; Rupprecht HJ
Z Kardiol; 2004; 93 Suppl 4():IV16-23. PubMed ID: 15085362
[TBL] [Abstract][Full Text] [Related]
7. CETP (cholesteryl ester transfer protein) promoter -1337 C>T polymorphism protects against coronary atherosclerosis in Japanese patients with heterozygous familial hypercholesterolaemia.
Takata M; Inazu A; Katsuda S; Miwa K; Kawashiri MA; Nohara A; Higashikata T; Kobayashi J; Mabuchi H; Yamagishi M
Clin Sci (Lond); 2006 Nov; 111(5):325-31. PubMed ID: 16822236
[TBL] [Abstract][Full Text] [Related]
8. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group.
Kuivenhoven JA; Jukema JW; Zwinderman AH; de Knijff P; McPherson R; Bruschke AV; Lie KI; Kastelein JJ
N Engl J Med; 1998 Jan; 338(2):86-93. PubMed ID: 9420339
[TBL] [Abstract][Full Text] [Related]
9. Interaction between a common variant of the cholesteryl ester transfer protein gene and the apolipoprotein E polymorphism: effects on plasma lipids and lipoproteins in a cohort of 7-year-old children.
Rump P; Mensink RP; Hornstra G
Nutr Metab Cardiovasc Dis; 2002 Dec; 12(6):317-24. PubMed ID: 12669678
[TBL] [Abstract][Full Text] [Related]
10. Enhanced cholesteryl ester transfer protein activities and abnormalities of high density lipoproteins in familial hypercholesterolemia.
Inazu A; Koizumi J; Mabuchi H; Kajinami K; Takeda R
Horm Metab Res; 1992 Jun; 24(6):284-8. PubMed ID: 1634194
[TBL] [Abstract][Full Text] [Related]
11. An interaction between the TaqIB polymorphism of cholesterol ester transfer protein and smoking is associated with changes in plasma high-density lipoprotein cholesterol levels in Turks.
Hodoğlugil U; Williamson DW; Huang Y; Mahley RW
Clin Genet; 2005 Aug; 68(2):118-27. PubMed ID: 15996208
[TBL] [Abstract][Full Text] [Related]
12. The cholesteryl ester transfer protein Taq1B gene polymorphism predicts clinical benefit of statin therapy in patients with significant coronary artery disease.
Carlquist JF; Muhlestein JB; Horne BD; Hart NI; Bair TL; Molhuizen HO; Anderson JL
Am Heart J; 2003 Dec; 146(6):1007-14. PubMed ID: 14660992
[TBL] [Abstract][Full Text] [Related]
13. Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: individual patient meta-analysis of 13,677 subjects.
Boekholdt SM; Sacks FM; Jukema JW; Shepherd J; Freeman DJ; McMahon AD; Cambien F; Nicaud V; de Grooth GJ; Talmud PJ; Humphries SE; Miller GJ; Eiriksdottir G; Gudnason V; Kauma H; Kakko S; Savolainen MJ; Arca M; Montali A; Liu S; Lanz HJ; Zwinderman AH; Kuivenhoven JA; Kastelein JJ
Circulation; 2005 Jan; 111(3):278-87. PubMed ID: 15655129
[TBL] [Abstract][Full Text] [Related]
14. Cholesteryl ester transfer protein activity and cardiovascular events in patients with chronic kidney disease stage V.
Seiler S; Schlitt A; Jiang XC; Ulrich C; Blankenberg S; Lackner KJ; Girndt M; Werdan K; Buerke M; Fliser D; Heine GH
Nephrol Dial Transplant; 2008 Nov; 23(11):3599-604. PubMed ID: 18503096
[TBL] [Abstract][Full Text] [Related]
15. On-statin cholesteryl ester transfer protein mass and risk of recurrent coronary events (from the pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 [PROVE IT-TIMI 22] study).
Khera AV; Wolfe ML; Cannon CP; Qin J; Rader DJ
Am J Cardiol; 2010 Aug; 106(4):451-6. PubMed ID: 20691300
[TBL] [Abstract][Full Text] [Related]
16. Plasma levels of cholesteryl ester transfer protein and the risk of future coronary artery disease in apparently healthy men and women: the prospective EPIC (European Prospective Investigation into Cancer and nutrition)-Norfolk population study.
Boekholdt SM; Kuivenhoven JA; Wareham NJ; Peters RJ; Jukema JW; Luben R; Bingham SA; Day NE; Kastelein JJ; Khaw KT
Circulation; 2004 Sep; 110(11):1418-23. PubMed ID: 15337694
[TBL] [Abstract][Full Text] [Related]
17. Cholesteryl ester transfer protein TaqIB polymorphism and its relation to parameters of the insulin resistance syndrome in an Austrian cohort.
Weitgasser R; Galvan G; Malaimare L; Derflinger I; Hedegger M; Lang J; Iglseder B; Ladurner G; Paulweber B
Biomed Pharmacother; 2004 Dec; 58(10):619-27. PubMed ID: 15589073
[TBL] [Abstract][Full Text] [Related]
18. Smaller low-density lipoprotein size as a possible risk factor for the prevalence of coronary artery diseases in haemodialysis patients: associations of cholesteryl ester transfer protein and the hepatic lipase gene polymorphism with low-density lipoprotein size.
Kimura H; Miyazaki R; Imura T; Masunaga S; Shimada A; Mikami D; Kasuno K; Takahashi N; Hirano T; Yoshida H
Nephrology (Carlton); 2011 Aug; 16(6):558-66. PubMed ID: 21352420
[TBL] [Abstract][Full Text] [Related]
19. No physical activity x CETP 1b.-629 interaction effects on lipid profile.
Bernstein MS; Costanza MC; James RW; Morris MA; Cambien F; Raoux S; Morabia A
Med Sci Sports Exerc; 2003 Jul; 35(7):1124-9. PubMed ID: 12840632
[TBL] [Abstract][Full Text] [Related]
20. Association of cholesteryl ester transfer protein -629C > A polymorphism with high-density lipoprotein cholesterol levels in coronary artery disease patients.
Tanrikulu S; Ademoglu E; Gurdol F; Mutlu-Turkoglu U; Bilge AK; Nisanci Y
Cell Biochem Funct; 2009 Oct; 27(7):452-7. PubMed ID: 19784962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
